Vivus
INVA$899M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBURLINGAME
Drugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Mar 31, 2026
7wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
VI-0609 Phase 2 Results Expected
Mar 31, 2026VI-060949
Primary completion for VI-0609 trial (NCT06915246) in Lymphoma
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
VI-0521
Obesity
avanafil
Erectile Dysfunction
VI-1121
Alzheimer's Disease
Phentermine/Topiramate
Diabetes
Topical alprostadil (PGE-1)
Sexual Dysfunction, Physiological
VI-0609
Lymphoma
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
VI-0521 | Phase 3 | Obesity | - |
avanafil | Phase 3 | Erectile Dysfunction | - |
VI-1121 | Phase 2 | Alzheimer's Disease | - |
Phentermine/Topiramate | Phase 2 | Diabetes | - |
Topical alprostadil (PGE-1) | Phase 2 | Sexual Dysfunction, Physiological | - |
VI-0609 | Phase 2 | Lymphoma | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
INVA News